Navigation Links
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
Date:6/4/2009

EXTON, Pa., June 4 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the baseline LaunchTrends(TM): SIMPONI report. The survey was completed by U.S. Rheumatologists in May 2009, just days after the FDA announced approval for SIMPONI (golimumab).

Once monthly dosing seems to be playing well, according to the Rheumatologists in the study who anticipate relatively quick uptake of SIMPONI. 84% of the Rheumatologists surveyed report that they intend to use SIMPONI within the next six months, and a fair proportion intend to incorporate SIMPONI into their armamentarium right away. The majority of RA patients likely to be placed on SIMPONI are expected to be switched from current biologic agents, primarily impacting use of Enbrel, Humira and Remicade. The main advantages that clinicians perceive for SIMPONI compared to currently available agents are the monthly dosing regimen and self injection. On the downside, SIMPONI is a new addition to an already crowded market of TNF agents with a similar mechanism of action and a lack of any clear clinical differentiation. Concern was also expressed about the lack of radiographic data at the time of launch to support the drug's ability to slow the progression of disease.

Adding to the competitive environment, the FDA approved UCB's CIMZIA(R) (certolizumab) for Rheumatoid Arthritis on May 14th, bringing yet another once monthly TNF agent into the mix. In addition to the recent launches of SIMPONI and CIMZIA there is significant interest among Rheumatologists in Roche's ACTEMRA(R) (tocilizumab), an IL-6 blocker currently under review with the FDA. When presented with all three products, interest was highest for ACTEMRA.

LaunchTrends(TM) measures launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at one month post launch, will be fielded on June 22 and will be expanded to include CIMZIA in the competitive set. The results will be published in mid-July.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact Paul Callahan at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Monthly Investor Conference Call
2. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. National Council on Disability Monthly Bulletin for February, 2009
4. U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6
5. Medical City Hospital Named by Texas Monthly as One of the Top Ten Best Companies to Work for in Texas
6. National Council on Disability Monthly Bulletin for November 2008
7. Renowned Thoracic Surgeon Recognized as Top Doctor by Peers in Annual New Jersey Monthly Magazine Survey
8. National Council on Disability Monthly Bulletin for October 2008
9. National Council on Disability Monthly Bulletin for June, 2008
10. National Council on Disability Monthly Bulletin for March 2008
11. National Council on Disability Monthly Bulletin for February, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... injectable drug delivery systems, today announced that it will release ... December 31, 2015 after market close on February 9, 2016. ... call to discuss these financial results.    About ... --> About Unilife Corporation ...
(Date:2/8/2016)... NORTHBROOK, Ill. , Feb. 8, 2016  Astellas Pharma ... today announced the promotion of James Robinson as ... the company,s operations in North and South America ... president, Astellas Pharma US, representing the commercial organization in ... assumed in 2013. Masao Yoshida , who ...
(Date:2/8/2016)... Palatin Technologies, Inc. (NYSE MKT: PTN), ... for the treatment of diseases with significant unmet ... the United States Patent and Trademark Office (USPTO) ... Patent Application Serial Number 14/313,258 (the ,258 application).  ... female sexual dysfunction using the formulation and dose ...
Breaking Medicine Technology: